£279 Million Investment! The UK to Explore Utilizing Eli Lilly's Weight Loss Drug to Help Citizens Return to Work

The British government is planning a study to assess whether a new weight-loss drug from US pharmaceutical giant Eli Lilly can help people regain their ability to work and have a positive impact on tackling high rates of long-term disease. Long-term illness has become one of the major obstacles to economic development in the UK. At a flagship summit hosted by British Prime Minister Keir Starmer, Eli Eli announced an investment plan of up to 279 million pounds ($365.4 million) aimed at competing with Novo Nordisk's Ozempic, British Health Minister Steve Barclay predicted. The use of this drug will help improve the overall health of the UK population.

The investment plan includes a large-scale "real world study" of tirzepatide, developed by Eli Lilly and Co., which is marketed in the U.K. as Mounjaro. The drug is intended to reduce the burden on Britain's National Health Service (NHS). Streeting said obesity costs the NHS 11 billion pounds a year, leading to people taking more sick days and even dropping out of the workforce altogether.

Writing in The Daily Telegraph, Dr Streeting said: 'The long-term benefits of these drugs could have significant implications for our approach to tackling obesity. He further elaborated: "For many people, these weight loss drugs will be life-changing, helping them return to work and easing the pressure on the NHS."

The University of Manchester will coordinate the study, which is expected to involve 3,000 participants. Data will be collected on participants' "health-related quality of life, employment status, and changes in sick leave." Just earlier this month, the NHS in England had outlined a plan to offer the drug to nearly 250,000 people as part of a three-year plan.

Streeting stressed that while the drug is an effective tool to tackle obesity, people also need to change their lifestyles to avoid further strain on an already overstretched health service after years of health crises. "We cannot always expect the NHS to pay for unhealthy lifestyles," he points out.

Amanda Pritchard, chief executive of NHS England, said the research would provide valuable insights into the health service. "Obesity is one of the biggest public health issues we face and we know that weight loss drugs are a game changer," she said.